Co-Branded Lab ReportFree 90-day trial · walk-away clauseSub-200ms · audit-logged · CPIC-graded

Your lab's logo. India-calibrated dosing report.

A diagnostic lab POSTs a genotype to the IndoPGx API and receives a clinician-ready, CPIC-graded, India-allele-frequency-calibrated PDF carrying the lab's logo. This is the artifact. Section 3 — the India calibration panel showing IndiGen frequency vs gnomAD SAS vs gnomAD global — is the differentiator no other Indian PGx tool ships.

The trial wrapper: Free 90-day API trial. Lab co-brands the PDF output. If it doesn't lift clinician satisfaction, you walk — no cost, no lock-in. Decision-support positioning throughout (no DCGI/CDSCO gating). Lab keeps all patient data; we keep only aggregate model-improvement signals.

1 · Lab branding
2 · Patient genotype
Click any preset above, or enter your own diplotype.

The 90-day trial offer

Per the IndoPGx GTM playbook §4.4: every diagnostic lab gets a free 90-day API trial with co-branded PDF output and a walk-away clause. No DCGI/CDSCO gating because positioning is decision support throughout. Five things in the trial agreement (§4.5):

1
Decision-support positioning
Not a medical-device claim. Lets a lab sign without DCGI/CDSCO gates.
2
Lab keeps data; we keep aggregate
They keep all patient/cohort data. We retain only aggregate model-improvement signals.
3
Co-branded PDF output
Their logo on the report. They champion you internally.
4
One narrow gene-drug pair to start
CYP2C19 + clopidogrel only. Prove it, then expand to NUDT15, G6PD, CYP2D6, CYP2C9.
5
A success metric agreed up front
Clinician alert-acceptance rate, or TAT from genotype → dosing guidance. Measure, document.
Decision support within the CPIC framework, not a medical device. Co-branded reports are customer-facing artifacts; lab maintains responsibility for clinical interpretation.